News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel

News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel
Sign In

Dako Announces Digital Pathology Agreements with Philips and Omnyx

Goal is to deliver integrated digital pathology solutions to clinical pathology laboratories


Yesterday, Dako announced separate digital pathology agreements with Royal Philips Electronics (NYSE: PHG) and Omnyx, LLC. Both the Philips and Omnyx agreements give each company access to Dako’s proprietary software algorithms and reagents used in tissue analysis for certain cancers.

In the deal between Philips and Dako, Philips plans to incorporate certain of Dako’s image analysis applications to the digital pathology system it is currently developing. Breast cancer is the diagnostic area covered by this new agreement. Philips will get access to Dako’s image analysis software for tissue-based breast cancers diagnosis, in tandem with Dako’s reagents for staining HER2, Estrogen Receptor (ER), Progesterone Receptor (PR), p53 and Ki-67 proteins.

(more…)

“Poorly-Developed” Clinical Pathology Laboratory Tests Subject of New York Times Story

Times reporter looks at issues affecting accuracy of different breast cancer tests


Pathologists should consider a recent story about breast cancer testing in the New York Times to be a warning flag, similar to the warning flags that the Coast Guard flies along the coast to warn of an approaching hurricane. The subject of the story was “unclear tests” used to identify whether a breast cancer patient is a candidate for certain therapeutic drugs.

The New York Times story was in response to the public release of new guidelines for processing specimens used in estrogen receptor and progesterone receptor (ER/PR) testing for breast cancer. The guidelines were announced by the College of American Pathologists and American Society of Clinical Oncology (ASCO) on April 19, 2010. One goal of the new guidelines is to improve “the accuracy of immunohistochemistry (IHC) testing for the expression status of estrogen (ER) and progesterone receptors (PgR) in breast cancer” as performed by the hundreds of anatomic pathology laboratories in the United States which perform ER and PR testing.

(more…)

Digital Pathology Moves Forward with Two New Digital Imaging Products

Aperio Technologies and Applied Spectral Imaging announce new products in July

Two new digital imaging products launched this month show that vendors are advancing the capabilities of digital imaging and digital pathology systems. Each company’s new product announcement touts the value of computer-aided diagnosis and computer pattern recognition for anatomic pathologists.

On July 9, Aperio Technologies, Inc., of Vista, California, launched its Digital IHC Solution for immunohistochemistry that features integrated image analysis for quantification of breast cancer. Aperio says that this is the only commercially available FDA-cleared system that allows pathologists to run quantitative IHC image analysis while reading slides on a computer monitor.
(more…)

;